Immunofluorescence Assay Market Size, Share, Growth, Trends | Report 2022-2030
The global immunofluorescence assay market was estimated at USD 2.55 billion in 2021 and it is expected to surpass around USD 4.61 billion by 2030, poised to grow at a CAGR of 6.8% from 2022 to 2030.
Immunofluorescence assay is a technique used in virology for the detection of antibodies by its selective ability to react with the antigen present in the infected cell. For this purpose, fluorescent dyes are used. It is one of the applied techniques of light microscopy. The results obtained from the techniques of ELISA and MFIA are confirmed using immunofluorescence assay (IFA). The technique is applied to specific sections of tissues, cells, and cell line cultures. It is used to analyze small molecules, proteins, and glycan’s. The requirements of the assay are a reagent kit, antibodies specific to antigens, imaging equipment and assay kit.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 2.55 billion |
| Revenue Forecast by 2030 | USD 4.61 billion |
| Growth rate from 2022 to 2030 | CAGR of 6.8% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, Product, Application, End user, Region |
| Companies Covered |
Thermo Fisher Scientific Inc., MaxVision Biosciences Inc., Olympus Corporation, AESKU GROUP GmbH, Danaher Corporation, Bio-Rad Laboratories Inc., Merck KGaA, Bruker Corporation, Sino Biological Inc., Enzo Biochem Inc., Dikinson and Company, Cell Signaling Technology Inc., Bio Tek Instruments, Inc., Zyagen, BioLegend Inc. among others |
The two classes of immunofluorescence are as follows -
Over the last few decades, the prevalence of chronic disease like Chron’s disease, HIV, and Alzheimer’s has increased globally. A growing awareness regarding the detection and cure to these diseases are some of the driving factors for market growth. The major applications of immunofluorescence assay are antibody detection, antigen detection in cell culture and membranes, biopsy, and detection of spread immune cells, for example- Secondary (Indirect) Immunofluorescence Assay is used for detection of anticell membrane associated DNA Abs in juvenile systemic lupus erythematosus. In this Anti-cmDNA Abs and antinuclear Abs were detected in the patient serum using immunofluorescence and ELISA. Recently in April 2021, a company named Euroimmum launched a compact immunofluorescence microscope EPML (EUROPattern Microscope Live). EPML is an automated instrument that captures the image within 2 seconds. It has a 20x high camera resolution.
In IFA, the imaging equipment are used to detect the fluorescently linked antibodies in the sample. These instruments are quite advanced in features and expensive. So this can be a restraining factor for the market. Due to the increasing prevalence of the autoimmune diseases, chronic diseases, it takes maximum expenditure of healthcare and research services. The health insurance and growing medical reimbursement has a positive impact on the growing IFA market. However, increasing government funding in research services and surgical research services will boost the market.
The immunofluorescence assay market is segmented into type, product, application, end-user and region. The type segment is further bifurcated into direct immunofluorescence, and indirect immunofluorescence. The product segment is divided into antibodies, reagents, kits, instruments, consumables and accessories. The application segment is based upon autoimmune diseases, neurological diseases, clinical research and diagnostics, cardiovascular diseases and cancer. The end -user segment is based upon pharmaceutical and biotechnology companies, contract research organizations, hospitals and diagnostic centers. The region segment is further segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
The increasing prevalence of chronic diseases and infectious diseases is found to be the highest in North America and holds the highest share in the assay market. Moreover, the research is also supported through government funding and also developing the healthcare services that accelerates the market growth. Countries like India, China, and Brazil are expected to show a potential growth in the market in the near future. According to the research, India and China have a higher prevalence rate to diabetes that would boost the market. Middle East and Africa holds the least market share due to strict government policies, and poor economic development.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immunofluorescence Assay Market
5.1. COVID-19 Landscape: Immunofluorescence Assay Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immunofluorescence Assay Market, By Type
8.1. Immunofluorescence Assay Market, by Type, 2022-2030
8.1.1. Direct immunofluorescence (Primary)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Indirect immunofluorescence (Secondary)
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immunofluorescence Assay Market, By Product
9.1. Immunofluorescence Assay Market, by Product, 2022-2030
9.1.1. Antibodies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. reagents
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. kits
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. instruments
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. consumables and accessories
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immunofluorescence Assay Market, By Application
10.1. Immunofluorescence Assay Market, by Application, 2022-2030
10.1.1. Autoimmune Diseases
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Neurological Diseases
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Clinical Research and Diagnostics
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Cardiovascular Diseases
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Cancer
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Immunofluorescence Assay Market, By End user
11.1. Immunofluorescence Assay Market, by End user, 2022-2030
11.1.1. Pharmaceutical and Biotechnology Companies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Contract Research Organizations
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals and Diagnostic Centers
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Immunofluorescence Assay Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.4. Market Revenue and Forecast, by End user (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.4. Market Revenue and Forecast, by End user (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End user (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.4. Market Revenue and Forecast, by End user (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.4. Market Revenue and Forecast, by End user (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.4. Market Revenue and Forecast, by End user (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.4. Market Revenue and Forecast, by End user (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.4. Market Revenue and Forecast, by End user (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.4. Market Revenue and Forecast, by End user (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.4. Market Revenue and Forecast, by End user (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End user (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.4. Market Revenue and Forecast, by End user (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End user (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.4. Market Revenue and Forecast, by End user (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.4. Market Revenue and Forecast, by End user (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End user (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.4. Market Revenue and Forecast, by End user (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End user (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.4. Market Revenue and Forecast, by End user (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.4. Market Revenue and Forecast, by End user (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End user (2017-2030)
Chapter 13. Company Profiles
13.1. Thermo Fisher Scientific Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. MaxVision Biosciences Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Olympus Corporation
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Olympus Corporation
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Danaher Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bio-Rad Laboratories Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck KGaA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bruker Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sino Biological Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Enzo Biochem Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers